Raising FVE for Mesoblast After Adjusting for AUD as We Await 180 Day Survival Data in AGvHD

Mesoblast's Partner Receives Full Approval in Japan; Commercial Launch Ahead

Current Share Price Ascribes No Value to Chronic Heart Failure Potential, but Risk Still Very High

Lead Heart Trial Beats Faster for Mesoblast; Interim Analysis Encouraging

Leading Independent Investment Research, Morningstar, Inc.

Morningstar

Leading Independent Investment Research

Morningstar, Inc.

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. We offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors. 

Morningstar provides data on more than 500,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 16 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries, with more than $180 billion in assets under advisement or management as of June 30, 2015. We have operations in 27 countries.

Download the Morningstar Fact Sheet : http://corporate.morningstar.com/US/documents/MarketingFactSheets/AboutMorningstarFactsheet.pdf

Equity Bottom-Up

<p>No-moat <a href="https://www.smartkarma.com/entities/769" target="_blank" data-smartkarma-citation="entities:769:1">Mesoblast Ltd (MSB AU)</a> achieved a financial milestone in the first six months of fiscal 2018 by posting a maiden net profit after tax of USD 6.7 million, compared with a loss of USD 39 million in the prior corresponding period. Total revenue in the period of USD 14.6 million, compared with about USD 1 million in the PC, comprised royalties on sales of Temcell in Japan of USD 1.9 million and up-front payments of around USD 12.8 million from its patent license agreement with TiGenix. We…</p>

No-moat Mesoblast Ltd (MSB AU) achieved a financial milestone in the first six months of fiscal 2018 by posting a maiden net profit after tax of USD 6.7 million, compared with a loss of USD 39 million in the prior corresponding period. Total revenue in the period of USD 14.6 million, compared with about USD 1 million in the PC, comprised royalties on sales of Temcell in Japan of USD 1.9 million and up-front payments of around USD 12.8 million from its patent license agreement with TiGenix. We…

Mesoblast Books First-Half Profit and Moves Closer to FDA Approval in Pediatric AGvHD